Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
Generated Narrative: Evidence 236966
version: 64; Last updated: 2024-12-14 08:46:28+0000
Profile: ComparativeEvidence
url: https://fevir.net/resources/Evidence/236966
identifier: FEvIR Object Identifier/https://fevir.net/FOI/236966, outcomeId/313960, picoId/85798, sectionId/73215
name: End_stage_kidney_disease_from_MAGICapp_313960
title: MAGIC-derived Evidence: End-stage kidney disease with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
status: Active
publisher: Computable Publishing LLC
contact: support@computablepublishing.com
author: Computable Publishing®: MAGIC-to-FEvIR Converter:
| Code | Value[x] |
| Evidence Based Medicine on FHIR Implementation Guide Code System evidence-communication: Evidence Communication | ComparativeEvidence |
copyright:
https://creativecommons.org/licenses/by-nc-sa/4.0/
| Type | ResourceReference |
| Part Of | MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes (Identifier: FEvIR Linking Identifier/MAGIC-5288-j1Wqrn-conversion-report) |
description:
This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.
assertion:
There probably be no important difference between SGLT2 inhibitors and GLP-1 receptor agonists.
variableDefinition
description:
Adults with type 2 diabetes
variableRole: Population
variableDefinition
description:
GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA
variableRole: Exposure
comparatorCategory: GLP-1 RA
variableDefinition
description:
End-stage kidney disease
variableRole: Outcome
observed: End-stage kidney disease
synthesisType: SYSTEMATIC_REVIEW
studyDesign: randomized assignment
statistic
description:
Risk Difference -1.0% (CI95 -3.4% to 2.0%)
statisticType: Risk Difference
quantity: -0.01
SampleSizes
NumberOfStudies NumberOfParticipants 1 463 AttributeEstimates
Type Range CI95 -0.034-0.02
statistic
description:
OR 0.91 (CI95 0.69 to 1.2)
statisticType: Odds Ratio
quantity: 0.91
SampleSizes
NumberOfStudies NumberOfParticipants 1 463 AttributeEstimates
Type Range CI95 0.69-1.2
certainty
description:
Due to serious imprecision
type: Overall certainty
rating: Moderate certainty
Subcomponents
Type Rating Risk of Bias NOTSET Inconsistency NOTSET Indirectness NOTSET Imprecision NOTSET Publication Bias NOTSET
IG © 2024+ HL7 International / Clinical Decision Support. Package hl7.fhir.uv.ebm#2.0.0-ballot based on FHIR 6.0.0-ballot2. Generated 2024-12-19
Links: Table of Contents |
QA Report
| Version History |
|
Propose a change